Landscapes / Companies
Intra-Cellular Therapies, Inc. not checked
FollowEvery new trial, moved date and filing, and a Monday email
Drugs
2
in active trials · 6 in all
Trials
12 active
36 since 2021
Drugs2
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Atypical antipsychotic |
Approved | 5 Apr 2027Phase 3 trial completes | |||
| Next date | 5 Apr 2027 · Phase 3 trial completes | ||||
| Also tested for | Irritability Associated With Autism Spectrum Disorder, Major Depressive Disorder and 5 more | ||||
| Open drug page | |||||
— |
Phase 3 | 16 Mar 2027Phase 2 trial completes | |||
| Next date | 16 Mar 2027 · Phase 2 trial completes | ||||
| Also tested for | Generalized Anxiety Disorder, Psychotic Disorders and 2 more | ||||
| Open drug page | |||||
About
- No active trial
- ITI-333, Lenrispodun, Lumateperone LAI, Lumateperone Long-Acting
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 Industry-sponsored drug trials since 2021